The historical rank and industry rank for Turning Point Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
TPTX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.76 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -25.70% per year.
During the past 5 years, Turning Point Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -25.70% per year. The lowest was -34.20% per year. And the median was -29.95% per year.
Turning Point Therapeutics Price-to-Free-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Turning Point Therapeutics Price-to-Free-Cash-Flow Chart
Competitive Comparison of Turning Point Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Turning Point Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turning Point Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Turning Point Therapeutics's Price-to-Free-Cash-Flow falls into.
Turning Point Therapeutics Price-to-Free-Cash-Flow Calculation
Turning Point Therapeutics's Share Price of today is $76.01. Turning Point Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Turning Point Therapeutics (NAS:TPTX) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Turning Point Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Turning Point Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Turning Point Therapeutics (Turning Point Therapeutics) Business Description
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPTX has been successfully added to your 